Encision Signs Supply Agreement with Auris Health, Inc.

Encision与Auris Health公司签署供应协议。

2021-08-24 22:00:07 biospace

本文共1156个字,阅读需3分钟

Encision Inc. (PK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced that Encision has signed a Supply Agreement ("Agreement") with Auris Health, Inc. ("Auris"), part of the Johnson & Johnson Medical Devices Companies. The Agreement will have an initial term of three years. During the term, Auris has agreed to buy certain AEM® Technology enabled products exclusively from Encision. Encision will receive an upfront payment and upon achieving certain milestones, a milestone payment in addition to revenues from proprietary product sales to Auris per the terms of the Agreement. "We are happy to be teaming up with Auris to drive new levels of patient safety in robotic surgery. Encision's Active Electrode Monitoring is a proprietary and differentiating technology that shields patients and practitioners from radiant energy injuries during standard and robotic laparoscopic surgeries. We welcome this next phase to our relationship," said Gregory J. Trudel, President and CEO of Encision. Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM Technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31 2021 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise. CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com View original content:https://www.prnewswire.com/news-releases/encision-signs-supply-agreement-with-auris-health-inc-301361210.html SOURCE Encision Inc. Company Codes: OTC-BB:ECIA, OTC-PINK:ECIA
Encision Inc.(PK:ECIA)是一家拥有主动电极监测(AEM®)专利技术的医疗设备公司,该技术可防止微创手术中危险的分散电外科烧伤,该公司今天宣布,Encision已与强生医疗设备公司的一部分Auris Health,Inc.(“Auris”)签署了一项供应协议(“协议”)。 该协议的初始期限为三年。在此期间,Auris同意从Encision独家购买某些AEM®技术支持的产品。Encision将收到预付款,在实现某些里程碑后,除了根据协议条款向Auris销售专有产品的收入之外,还将收到里程碑付款。 “我们很高兴与Auris合作,推动机器人手术中患者安全的新水平。Encision的主动电极监测是一项专有和差异化的技术,在标准和机器人腹腔镜手术中保护患者和从业者免受辐射能伤害。Encision总裁兼首席执行官格雷戈里·J·特鲁德尔(Gregory J.Trudel)表示:”我们欢迎我们关系的下一阶段。“ Encision Inc.设计和销售一系列高性能外科器械,通过AEM技术、外科性能和医院广泛的微创外科手术的价值,在患者安全方面取得了进步。该公司总部设在科罗拉多州的博尔德,率先开发和部署了主动电极监测技术,AEM技术,以消除微创手术中危险的杂散能量烧伤。有关我们所有产品的更多信息,请访问www.encision.com。 根据1995年《私人证券诉讼改革法》的安全港条款,本公司注意到,本新闻稿和其他地方的陈述,包括历史信息以外的一切,涉及风险和不确定因素,可能导致实际结果与前瞻性陈述所表明的结果大相径庭。可能导致公司实际结果大不相同的因素包括,除其他外,其开发新的或改进的产品并使这些产品在市场上被接受的能力,其通过公司分销渠道增加净销售额的能力,其与其他手术器械制造商成功竞争的能力,新账户转换数量不足,资金不足,开发新产品和获得FDA批准这些新产品的延迟,以及公司提交给证券交易委员会的文件中讨论的其他因素。鼓励读者审查该公司截至2021年3月31日止年度10-K表年度报告中出现的风险因素和其他披露,以及随后向证券交易委员会提交的文件。我们不承担任何义务公开更新任何前瞻性陈述,无论是由于收到新信息、未来事件或其他原因。 联系人:Mala Ray,Encision Inc.,303-444-2600,mray@Encision.com 查看原文内容:https://www.prnewswire.com/news-releases/encision-signs-supply-agreement-with-auris-health-inc-301361210.html 来源Encision Inc. 公司代码:OTC-BB:ECIA,OTC-Pink:ECIA

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文